ceo gone, page-7

Worth a punt at 8.5c?

Downside is a capital raising at around 5c or lower per share. Or complete failure of business but then it is probably worth at least 5c per share in cash.

Upside is hard to define, but the IP could be worth something to a larger pharma. Or price creeps upwards on low volume as a new strategy (hopefully better than the last one) begins.

There is a lot of uncertainty here. Carpe Diem.